# Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

> **NCT06172036** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 180 (estimated)

## Conditions studied

- Neoadjuvant Chemotherapy
- Resectable Pancreatic Cancer

## Interventions

- **DRUG:** irinotecan liposome + oxaliplatin + 5-FU / LV
- **DRUG:** Adebellizumab

## Key facts

- **NCT ID:** NCT06172036
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01-20
- **Primary completion:** 2026-01-20
- **Final completion:** 2027-01-20
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172036, "Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06172036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*